AU2013203493B2 - Tamper resistant immediate release formulations - Google Patents

Tamper resistant immediate release formulations Download PDF

Info

Publication number
AU2013203493B2
AU2013203493B2 AU2013203493A AU2013203493A AU2013203493B2 AU 2013203493 B2 AU2013203493 B2 AU 2013203493B2 AU 2013203493 A AU2013203493 A AU 2013203493A AU 2013203493 A AU2013203493 A AU 2013203493A AU 2013203493 B2 AU2013203493 B2 AU 2013203493B2
Authority
AU
Australia
Prior art keywords
dosage form
immediate release
solid oral
active agent
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013203493A
Other languages
English (en)
Other versions
AU2013203493A1 (en
Inventor
Akwete L. Adjei
Sibao CHEN
Robert Joe Kupper
Vincent Mancinelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhodes Pharmaceuticals LP
Original Assignee
Rhodes Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013203493(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhodes Pharmaceuticals LP filed Critical Rhodes Pharmaceuticals LP
Publication of AU2013203493A1 publication Critical patent/AU2013203493A1/en
Application granted granted Critical
Publication of AU2013203493B2 publication Critical patent/AU2013203493B2/en
Priority to AU2016202846A priority Critical patent/AU2016202846B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013203493A 2012-03-02 2013-03-01 Tamper resistant immediate release formulations Active AU2013203493B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016202846A AU2016202846B2 (en) 2012-03-02 2016-05-04 Tamper resistant immediate release formulations

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261606156P 2012-03-02 2012-03-02
US61/606,156 2012-03-02
US201261724141P 2012-11-08 2012-11-08
US61/724,141 2012-11-08
PCT/IB2013/000444 WO2013128276A2 (en) 2012-03-02 2013-03-01 Tamper resistant immediate release formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202846A Division AU2016202846B2 (en) 2012-03-02 2016-05-04 Tamper resistant immediate release formulations

Publications (2)

Publication Number Publication Date
AU2013203493A1 AU2013203493A1 (en) 2013-09-19
AU2013203493B2 true AU2013203493B2 (en) 2016-02-04

Family

ID=48044945

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013203493A Active AU2013203493B2 (en) 2012-03-02 2013-03-01 Tamper resistant immediate release formulations
AU2016202846A Active AU2016202846B2 (en) 2012-03-02 2016-05-04 Tamper resistant immediate release formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016202846A Active AU2016202846B2 (en) 2012-03-02 2016-05-04 Tamper resistant immediate release formulations

Country Status (21)

Country Link
US (3) US11173155B2 (https=)
EP (2) EP3170492B1 (https=)
JP (2) JP6199321B2 (https=)
CN (2) CN104144681A (https=)
AR (1) AR090218A1 (https=)
AU (2) AU2013203493B2 (https=)
CA (1) CA2852042C (https=)
CL (1) CL2014002283A1 (https=)
EA (1) EA028224B1 (https=)
ES (2) ES2821773T3 (https=)
IL (1) IL234256B (https=)
IN (1) IN2014MN01901A (https=)
MX (1) MX354677B (https=)
NZ (1) NZ629468A (https=)
PE (1) PE20142320A1 (https=)
PH (1) PH12014501910B1 (https=)
SG (1) SG11201405011PA (https=)
TW (2) TW201722406A (https=)
UY (1) UY34651A (https=)
WO (1) WO2013128276A2 (https=)
ZA (1) ZA201405960B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015065547A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EA032013B1 (ru) * 2013-10-31 2019-03-29 Сайма Лэбс Инк. Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
AU2015237721B2 (en) * 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6696994B2 (ja) * 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
US20160310437A1 (en) * 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
CA2983640A1 (en) * 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
CA2983638A1 (en) * 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a powder
MX2017013643A (es) * 2015-04-24 2018-03-08 Gruenenthal Gmbh Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
US20180185352A1 (en) * 2015-06-09 2018-07-05 KVK-Tech, Inc. Abuse deterrent pharmaceutical compositions
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3522890A4 (en) 2016-10-10 2020-06-03 Rhodes Pharmaceuticals L.P. PHARMACEUTICAL RESINATE COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3558300B1 (en) * 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
IL311303B1 (en) 2017-10-09 2026-01-01 Rhodes Pharmaceuticals Lp Medicinal resin components and methods for their production and use
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP4333646A2 (en) * 2021-05-03 2024-03-13 Cambridge Glycoscience Ltd Soluble and insoluble saccharide compositions and related methods
KR20240160583A (ko) * 2022-02-09 2024-11-11 드로타스타 엘엘씨 진경제와 항불안제의 약학 복합제

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
WO2004069135A2 (en) * 2003-02-05 2004-08-19 Ethypharm Composition comprising a mixture of active principles, and method of preparation
US20050112195A1 (en) * 2003-09-26 2005-05-26 Evangeline Cruz Drug coating providing high drug loading and methods for providing same
WO2005046684A1 (en) * 2003-11-04 2005-05-26 Shire Laboratories, Inc. Once daily dosage forms of trospium
US20060210630A1 (en) * 2004-09-30 2006-09-21 Likan Liang Controlled release compositions of gamma-hydroxybutyrate
WO2007120135A1 (en) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Lercanidipine immediate release composition
WO2008012474A2 (fr) * 2006-07-28 2008-01-31 Bouchara-Recordati Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP1967183A1 (en) * 2005-12-28 2008-09-10 Takeda Pharmaceutical Company Limited Controlled release solid preparation
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
WO2010066034A1 (en) * 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
WO2010069050A1 (en) * 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
WO2013038267A1 (en) * 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6740341B1 (en) 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
DE20220917U1 (de) * 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
WO2006124890A1 (en) * 2005-05-13 2006-11-23 Alpharma, Inc. Morphine sulphate formulations
WO2007126136A2 (en) * 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Mask- tasting solid preparation of pioglitazone
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
US20100151034A1 (en) * 2008-09-30 2010-06-17 Astellas Pharma Inc. Granular pharmaceutical composition of atorvastatin for oral administration
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
EP2493452B1 (en) * 2009-10-28 2013-07-17 Basf Se Stable protective coatings for pharmaceutical dosage forms
JP2014522849A (ja) 2011-06-29 2014-09-08 アラーガン インコーポレイテッド ヒドロキシステアリン酸マクロゴール１５製剤

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
WO2004069135A2 (en) * 2003-02-05 2004-08-19 Ethypharm Composition comprising a mixture of active principles, and method of preparation
US20050112195A1 (en) * 2003-09-26 2005-05-26 Evangeline Cruz Drug coating providing high drug loading and methods for providing same
WO2005046684A1 (en) * 2003-11-04 2005-05-26 Shire Laboratories, Inc. Once daily dosage forms of trospium
US20060210630A1 (en) * 2004-09-30 2006-09-21 Likan Liang Controlled release compositions of gamma-hydroxybutyrate
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP1967183A1 (en) * 2005-12-28 2008-09-10 Takeda Pharmaceutical Company Limited Controlled release solid preparation
WO2007120135A1 (en) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Lercanidipine immediate release composition
WO2008012474A2 (fr) * 2006-07-28 2008-01-31 Bouchara-Recordati Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
WO2010066034A1 (en) * 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
WO2010069050A1 (en) * 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
WO2013038267A1 (en) * 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AL-TAANI BASHAR, M. et al., 'Effect of microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium.' AAPS PHARMSCITECH, 2003, vol. 4, no. 3, Article 43 *
ASLANI, P. et al, 'EFFECT OF GELATION CONDITIONS AND DISSOLUTION MEDIA ON THE RELEASE OF PARACETAMOL FROM ALGINATE GEL BEADS' JOURNAL OF MICROENCAPSULATION, 1996, Vol .13, No. 5, pages 601-614 *
HEINZE. T. et al., 'Carboxymethyl Ethers of Cellulose and Starch - A Review', MACROMOLECULAR SYMPOSIA, 2005, Vol. 223, pages 13-39 *
KOHANE, D. S. et al., 'pH-triggered release of macromolecules from spray-dried polymethacrylate microparticles', PHARMACEUTICAL RESEARCH, 2003, Vol . 20, No. 10 pages 1533-1538 *

Also Published As

Publication number Publication date
US20240423974A1 (en) 2024-12-26
CN109820830A (zh) 2019-05-31
EA201400972A1 (ru) 2015-02-27
US12128042B2 (en) 2024-10-29
AU2016202846A1 (en) 2016-05-26
NZ629468A (en) 2017-08-25
AU2016202846B2 (en) 2017-06-01
CL2014002283A1 (es) 2015-04-17
AR090218A1 (es) 2014-10-29
AU2013203493A1 (en) 2013-09-19
PH12014501910A1 (en) 2014-11-24
US20150030677A1 (en) 2015-01-29
JP6199321B2 (ja) 2017-09-20
CN104144681A (zh) 2014-11-12
SG11201405011PA (en) 2014-09-26
TW201350142A (zh) 2013-12-16
US11173155B2 (en) 2021-11-16
US20220031693A1 (en) 2022-02-03
MX2014010534A (es) 2015-05-11
TWI614037B (zh) 2018-02-11
ES2619574T3 (es) 2017-06-26
EA028224B1 (ru) 2017-10-31
PH12014501910B1 (en) 2014-11-24
IN2014MN01901A (https=) 2015-07-10
JP6509287B2 (ja) 2019-05-08
CA2852042A1 (en) 2013-09-06
ES2821773T3 (es) 2021-04-27
ZA201405960B (en) 2016-03-30
TW201722406A (zh) 2017-07-01
CA2852042C (en) 2018-05-01
EP2819653A2 (en) 2015-01-07
WO2013128276A3 (en) 2013-12-27
EP3170492B1 (en) 2020-07-08
JP2015511953A (ja) 2015-04-23
IL234256B (en) 2020-08-31
MX354677B (es) 2018-03-15
JP2018012711A (ja) 2018-01-25
WO2013128276A2 (en) 2013-09-06
UY34651A (es) 2013-09-30
EP2819653B1 (en) 2017-01-11
EP3170492A1 (en) 2017-05-24
PE20142320A1 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
US12128042B2 (en) Tamper resistant immediate release formulations
US10517832B2 (en) Tamper resistant pharmaceutical formulations
AU2012310251B2 (en) Tamper resistant immediate release formulations
CA2847613A1 (en) Tamper resistant immediate release formulations
KR101701013B1 (ko) 부정조작 방지 즉각 방출 제형

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)